Good evening,
‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ 
 
 

Good evening,

There was one company on everyone's lips all of Tuesday.

Nasdaq-listed Moderna sent markets around the world higher after announcing promising results in an early-stage COVID-19 vaccine trial.

Tonight, we take a look at which Aussie fund manager couldn't be happier with the news. The fund in question has backed the US biotech for 18 months and first invested at about $US23 a share. Moderna shares closed on Tuesday at $US80.

Elsewhere, we take a look at what corporate activity has been going on at smash repairer AMA Group and provide an update on two emergency raisings.

Happy reading,
Sarah Thompson, Anthony Macdonald and Tim Boyd
Street Talk Editors

Street Talk

Platinum unearths COVID-19 vaccine hot stock

An 18-month position in a US biotech is reaping some serious paper gains for Australia's Platinum Asset Management.

Street Talk

AMA Group spurns approach, sticks to Plan A

Tyrekickers need not knock around smash repairer AMA Group. 

Street Talk

Kalium's brokers ask cornerstones to step up

It's go time at potash play Kalium Lakes. 

Street Talk

Big discount for little Decmil has fundies looking

Desperate Decmil Group has asked fund managers for one more shot at the big time. 

Street Talk

Ticketek owner TEG nabs ex-Goldman banker for M&A

It shouldn't take this next hire too long to get comfortable in his new role. 

 
The Australian Financial Review

The Daily Habit Of Successful People

Twitter Instagram LinkedIn Facebook

You have received this email because you are subscribed to with the email address: newsletter@newslettercollector.com

  Manage Subscriptions     Unsubscribe     Privacy Policy     Contact Us  

© 2020 The Australian Financial Review

38 - 42 Pirrama Rd Pyrmont, NSW 2009 Australia

 
Fairfax Media Limited, 38 - 42 Pirrama Rd, Pyrmont, NSW, 2009, Australia Profile center